$3.63
-0.01-0.27%
At Close: -
$3.60
-0.03-0.83%
After Hours: Jul 19, 4:22 PM EDT
15 minutes delayed
Comments
Loading...
G1 Therapeutics
GTHXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
G1 Therapeutics (NASDAQ:GTHX) Stock, Analyst Ratings, Price Targets, Forecasts
G1 Therapeutics Inc has a consensus price target of $16 based on the ratings of 7 analysts. The high is $56 issued by Roth Capital on September 1, 2021. The low is $3 issued by HC Wainwright & Co. on June 25, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Needham on June 25, 2024, June 25, 2024, and June 13, 2024, respectively. With an average price target of $7 between HC Wainwright & Co., Needham, and Needham, there's an implied 94.44% upside for G1 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Wedbush
EF Hutton
Raymond James
1calculated from analyst ratings
Analyst Ratings for G1 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | -16.67% | HC Wainwright & Co. | Edward White | $9 → $3 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 66.67% | Needham | Gil Blum | $12 → $6 | Maintains | Buy | Get Alert |
| 06/13/2024 | Buy Now | 233.33% | Needham | Gil Blum | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 150% | HC Wainwright & Co. | Edward White | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 233.33% | Needham | Gil Blum | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 150% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 233.33% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 150% | HC Wainwright & Co. | Edward White | → $9 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 233.33% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 233.33% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 233.33% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2024 | Buy Now | 11.11% | Wedbush | David Nierengarten | $5 → $4 | Maintains | Outperform | Get Alert |
| 02/13/2024 | Buy Now | 233.33% | Needham | Gil Blum | $14 → $12 | Maintains | Buy | Get Alert |
| 01/24/2024 | Buy Now | 288.89% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | Buy Now | 288.89% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | 38.89% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | Buy Now | — | JP Morgan | Anupam Rama | — | Downgrade | Neutral → Underweight | Get Alert |
| 08/03/2023 | Buy Now | 38.89% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 427.78% | EF Hutton | Tony Butler | → $19 | Reiterates | → Buy | Get Alert |
| 08/02/2023 | Buy Now | 288.89% | Needham | Gil Blum | $18 → $14 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 400% | Needham | Gil Blum | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
| 05/04/2023 | Buy Now | 122.22% | Raymond James | Dane Leone | $24 → $8 | Maintains | Outperform | Get Alert |
| 04/19/2023 | Buy Now | 400% | Needham | Gil Blum | → $18 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | 400% | Needham | Gil Blum | $31 → $18 | Maintains | Buy | Get Alert |
| 02/14/2023 | Buy Now | 205.56% | HC Wainwright & Co. | Edward White | $34 → $11 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 427.78% | EF Hutton | Tony Butler | $35 → $19 | Maintains | Buy | Get Alert |
| 01/30/2023 | Buy Now | 177.78% | JP Morgan | Anupam Rama | $7 → $10 | Upgrade | Underweight → Neutral | Get Alert |
| 01/05/2023 | Buy Now | 872.22% | EF Hutton | Tony Butler | → $35 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 761.11% | Needham | Gil Blum | $32 → $31 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 1483.33% | HC Wainwright & Co. | Edward White | $67 → $57 | Maintains | Buy | Get Alert |
| 09/16/2022 | Buy Now | 594.44% | Wedbush | David Nierengarten | $20 → $25 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 788.89% | Needham | Gil Blum | $42 → $32 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 1066.67% | Needham | Gil Blum | $44 → $42 | Maintains | Buy | Get Alert |
| 11/04/2021 | Buy Now | 427.78% | JP Morgan | Anupam Rama | — | Downgrade | Neutral → Underweight | Get Alert |
| 11/04/2021 | Buy Now | 1872.22% | HC Wainwright & Co. | Edward White | — | Maintains | Buy | Get Alert |
| 11/04/2021 | Buy Now | 566.67% | Raymond James | Dane Leone | — | Maintains | Outperform | Get Alert |
| 09/30/2021 | Buy Now | 455.56% | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/01/2021 | Buy Now | 1455.56% | Roth Capital | Tony Butler | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for G1 Therapeutics (GTHX) stock?
The latest price target for G1 Therapeutics (NASDAQ:GTHX) was reported by HC Wainwright & Co. on June 25, 2024. The analyst firm set a price target for $3.00 expecting GTHX to fall to within 12 months (a possible -16.67% downside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for G1 Therapeutics (GTHX)?
The latest analyst rating for G1 Therapeutics (NASDAQ:GTHX) was provided by HC Wainwright & Co., and G1 Therapeutics maintained their buy rating.
When was the last upgrade for G1 Therapeutics (GTHX)?
The last upgrade for G1 Therapeutics Inc happened on January 30, 2023 when JP Morgan raised their price target to $10. JP Morgan previously had an underweight for G1 Therapeutics Inc.
When was the last downgrade for G1 Therapeutics (GTHX)?
The last downgrade for G1 Therapeutics Inc happened on October 6, 2023 when JP Morgan changed their price target from N/A to N/A for G1 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for G1 Therapeutics (GTHX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of G1 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for G1 Therapeutics was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating G1 Therapeutics (GTHX) correct?
While ratings are subjective and will change, the latest G1 Therapeutics (GTHX) rating was a maintained with a price target of $9.00 to $3.00. The current price G1 Therapeutics (GTHX) is trading at is $3.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.